PPARdelta has anti-diabetic properties

Scientists have used quantitative analysis processes to investigate the contrasting roles that Peroxisome Proliferator-Activated Receptor (PPARgamma) and Peroxisome Proliferator-Activated Receptor (PPARdelta) play in regulating metabolism in adipose tissue.

In a study published by Genome Biology, a team from the University of Cambridge sought to understand the role PPARgamma and PPARdelta could potentially play in the treatment of insulin resistance.

While the part played by PPARgamma in regulating insulin sensitivity has been well researched, little has been discovered about PPARdelta due to a relative scarcity of selective PPARdelta agonists.

Using quantitative analysis processes, the scientists looked into the receptors contrasting roles and determined that while PPARgamma activation is characterised by increased fat storage, synthesis andelongation, PPARdelta activation caused increased fatty acid beta-oxidation,tricarboxylic acid cycle rate and oxidation of extracellular branch chainamino acids.

In conclusion, the study revealed that the PPARdelta has anti-diabetic and anti-obesity effects, brought about by a decrease in fatty acid synthesis and fat storage within synthesised TAG depot.